I've been compiling pooled data on ALT normalization rates across GLP-1 receptor agonist trials. This is relevant because persistently elevated ALT is the most accessible biomarker for ongoing hepatocyte injury in MASH, and normalization (ALT <40 U/L in men, <31 U/L in women, or <19 ULN depending on the reference) strongly correlates with histological improvement. Pooled ALT normalization rates at 48-72 weeks: | Drug | Dose | ALT Normalization | Mean ALT Reduction | Source | |------|------|-------------------|-------------------|--------| | Semaglutide | 2.4mg weekly | 51-59% | -22 to -28 U/L | STEP trials, Phase 2 NASH | | Tirzepatide | 15mg weekly | 62-74% | -26 to -34 U/L | SURPASS, SYNERGY-NASH | | Survodutide | 6mg weekly | 76% | -38 U/L | Phase 2b | | Liraglutide | 1.8mg daily | 38-42% | -14 to -18 U/L | LEAN trial | | Dulaglutide | 1.5mg weekly | 28-35% | -11 to -15 U/L | Post-hoc analyses | Key observations: 1. There's a clear potency gradient: survodutide > tirzepatide > semaglutide > liraglutide > dulaglutide. This roughly tracks with weight loss efficacy but isn't perfectly correlated — suggesting direct hepatic effects beyond weight reduction. 2. ALT normalization rates exceed what you'd predict from weight loss alone. In bariatric surgery cohorts with comparable weight loss, ALT normalization is ~55-60% at 12 months. Semaglutide achieves similar rates with less weight loss, suggesting a direct hepatoprotective mechanism. 3. The timeline matters. Most GLP-1 trials show rapid ALT improvement in the first 12-24 weeks (likely reflecting reduced steatosis and inflammation), followed by a slower continued improvement through 48-72 weeks (likely reflecting early fibrosis regression). 4. Baseline ALT is the strongest predictor of response. Patients with ALT >60 U/L show the most dramatic absolute reductions but lower normalization rates. Patients with ALT 40-60 have the highest normalization probability. Would love to hear from clinicians tracking ALT in their GLP-1 patients. Are you seeing these rates in real-world practice?

Great compilation. I'll share my real-world data — I track ALT systematically in all my MASH patients on GLP-1 therapy. My clinic cohort (last 18 months, all with baseline ALT >40): - Semaglutide patients (n=31): ALT normalization at 6 months = 45%, at 12 months = 52% - Tirzepatide patients (n=22): ALT normalization at 6 months = 54%, at 12 months = 64% These are slightly lower than the trial data, which I attribute to: 1. Real-world adherence is imperfect (supply issues, cost barriers, missed doses) 2. My patients are sicker on average (higher baseline fibrosis scores) 3. Some patients don't achieve optimal doses due to GI intolerance 4. Less rigorous lifestyle intervention than trial settings But the trends are absolutely consistent with what you've compiled. Tirzepatide patients do better on ALT, and the improvement is rapid — I typically see the biggest drop in the first 3 months. One pattern I've noticed that isn't in the trial data: patients who add structured exercise (particularly resistance training 3x/week) to their GLP-1 have notably better ALT normalization rates. In my cohort, exercisers hit ~70% normalization vs. ~40% in sedentary GLP-1 patients. This is observational and confounded, but the signal is strong.

The mechanistic question here is fascinating. Why do GLP-1 agonists reduce ALT more than expected from weight loss alone? Several proposed mechanisms: 1. Direct hepatocyte GLP-1 receptor activation: There are GLP-1 receptors on hepatocytes (though this is debated). Direct activation may reduce hepatocyte apoptosis and oxidative stress independent of metabolic effects. 2. Reduced hepatic de novo lipogenesis (DNL): GLP-1 agonists decrease insulin levels and hepatic insulin signaling, which reduces SREBP-1c-mediated DNL. Less intrahepatic fat = less lipotoxicity = less hepatocyte death = lower ALT. 3. Anti-inflammatory effects: GLP-1 agonists reduce TNF-alpha, IL-6, and CRP. Hepatic inflammation is a direct driver of hepatocyte necrosis (which is what ALT measures — it's a cell death marker). 4. Improved gut barrier function: GLP-1 agonists may reduce intestinal permeability and portal endotoxemia, reducing Kupffer cell activation and downstream hepatocyte injury. 5. Reduced visceral adiposity: Visceral fat releases free fatty acids directly into the portal circulation via lipolysis. GLP-1-mediated visceral fat loss reduces this FFA flux, decreasing hepatocyte lipotoxicity. The survodutide data is particularly informative because the glucagon component adds mechanisms 6 and 7: 6. Direct stimulation of hepatic fatty acid beta-oxidation 7. Activation of hepatic autophagy (lipophagy) This explains why survodutide's ALT normalization rate (76%) exceeds tirzepatide (62-74%) despite similar weight loss.

This is incredibly helpful. I'm a primary care physician trying to improve my MASH screening practices. A few practical questions: 1. What ALT threshold should trigger hepatology referral vs. in-house management with GLP-1 therapy? 2. If I start a patient on semaglutide for obesity and their ALT normalizes, does that mean their MASH is resolved? Or do they still need FibroScan/biopsy? 3. How often should I be checking ALT in my GLP-1 patients? 4. I have several patients whose ALT was slightly elevated (45-55), went on semaglutide, ALT normalized, but I never formally evaluated them for MASH. Should I go back and screen them with FibroScan? I feel like we're probably under-diagnosing MASH in primary care and I want to do better.

These are exactly the right questions. Here's what the current evidence and guidelines suggest: 1. Referral thresholds: - ALT > 2x ULN (>80 for men, >62 for women) — refer to hepatology - ALT persistently elevated + FIB-4 > 1.3 — refer to hepatology - ALT elevated + FibroScan > 8 kPa — refer to hepatology - Any ALT elevation + clinical features of advanced liver disease — refer urgently If ALT is 40-80 and FIB-4 < 1.3, you can manage in primary care with GLP-1/lifestyle and monitor. But get a FibroScan baseline if available. 2. ALT normalization =/= MASH resolution. ALT is a marker of hepatocyte injury, not fibrosis. A patient can have normalized ALT with persistent F2-F3 fibrosis (burned-out NASH). ALT normalization is encouraging but doesn't replace fibrosis assessment. FibroScan is the minimum; biopsy remains the gold standard for histological resolution. 3. ALT monitoring schedule on GLP-1: - Baseline before starting - 3 months after starting (to confirm trajectory) - Every 6 months thereafter - Annual comprehensive metabolic panel including AST, GGT, albumin, platelets 4. Retrospective screening: Yes, absolutely. If you have patients who had elevated ALT that normalized on GLP-1, they should still be screened for fibrosis. Calculate FIB-4 (it's free — just age, AST, ALT, platelets). If FIB-4 > 1.3, get a FibroScan. If FibroScan > 8 kPa, refer. You're not under-diagnosing — the entire healthcare system is. MASH affects ~5-6% of the population and the vast majority are undiagnosed. You asking these questions puts you ahead of most PCPs.